Clinical Data RisksRisks include negative clinical data, slower-than-expected development timelines, and setbacks in later-stage trials.
Competitive ThreatsIn Lilly's hands, STX-478 is a more significant threat, in our view.
Market PositionThe competitive landscape in the biotechnology sector poses a challenge for Relay Therapeutics' market position.